Skip to main
  1. Stocks
  2. Gain Therapeutics
  3. Forecast
GANX

Gain Therapeutics (GANX) Stock Forecast & Price Target

Gain Therapeutics (GANX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gain Therapeutics is attractive because its lead asset GT-02287 has shown consistent target engagement, favorable safety, and biomarker-driven evidence of mechanism in Phase 1a/1b, including an average 81% reduction in CSF glucosylsphingosine at Day 90 and durable MDS-UPDRS stability through Day 150. The case is strengthened by the program’s broad positioning in Parkinson’s disease with or without a GBA1 mutation, expanding Phase 2 plans across the U.S., Australia, and Europe, and by the fact that the FDA has authorized the IND. With approximately $13.1M in cash and cash equivalents at the midpoint of 2026 and a 2Q26 net loss of $0.11 per share, the company appears funded into next year while it advances a potentially disease-modifying platform and a second pipeline candidate, GT-04686.

Bears say

Gain Therapeutics is facing a weak fundamental case because the one-year mean in the 12 completers ended near baseline only after a six-point swing, while MDS-UPDRS II+III scores fluctuated from a 2.9-point improvement at Day 90 to 3.3 points above baseline at Day 270 and 0.5 points above baseline at Day 360. Such volatility, combined with four of 16 extension entrants excluded from the analysis, only two treatment-naive patients among the original 21, and no reported longitudinal medication or deep-brain-stimulation changes, makes it difficult to argue the data show durable disease stabilization. Although Gain reported no new extension safety signal, the liver-enzyme elevations, ALT/AST/GGT increases, and two hospitalized SAEs judged unlikely related still underscore clinical risk without clear efficacy clarity.

Gain Therapeutics (GANX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gain Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Gain Therapeutics (GANX) Analyst Forecast & Price Prediction

Get the latest Gain Therapeutics (GANX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Gain Therapeutics (GANX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gain Therapeutics (GANX) Forecast

Analysts have given Gain Therapeutics (GANX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Gain Therapeutics (GANX) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gain Therapeutics (GANX)


Gain Therapeutics (GANX) Analyst Forecast & Price Prediction

Get the latest Gain Therapeutics (GANX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Gain Therapeutics (GANX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GANX stock data and trends